The tirzepatide injection in Singapore: two indications, one medicine

Tirzepatide has been registered in Singapore since 2023, and on its current registrations it carries two indications: type 2 diabetes, and weight management. That second half has a date on it, because the medicine has been registered here three separate times and the three generations do not all say the same thing. It is prescription-only. This article sets out what is registered, what the label says, what the trials measured, and one overseas approval that does not travel.

Availability in Singapore. This medicine is registered with Singapore's Health Sciences Authority, and its registered indication includes weight management. Which medicine suits a particular person, if any does, is decided by the doctor who assesses them — we do not promote a named product.

What is registered, and why the answer has a date on it

Eighteen products, in three generations (HSA register):

All are classified Prescription Only.

This is the part most coverage gets wrong, in both directions. Section 4.1 of the current registrations carries two headed indications (NDF). Section 4.1 of the 2023 injection registration carries one, and it is diabetes (NDF). Both pages are real, both are current, and a writer who reads either one alone comes away with half the picture.

The accurate sentence is that tirzepatide is registered in Singapore for weight management on its current registrations. A page saying otherwise is describing the 2023 entry.

The two indications, from the label

The type 2 diabetes indication covers adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise, either as monotherapy where metformin is inappropriate or alongside other diabetes medicines.

The weight management indication runs as an adjunct to a reduced-calorie diet and increased physical activity, in adults with an initial BMI of 30 kg/m² or above, or 27 to under 30 in the presence of at least one weight-related comorbid condition — the label names hypertension, dyslipidaemia, sleep apnoea, cardiovascular disease, prediabetes and type 2 diabetes as examples (NDF).

Both are written as an adjunct. The medicine was licensed alongside diet and activity because that is how it was trialled.

The label's BMI numbers, and ours

The label's floor for weight management is a BMI of 30, or 27 to under 30 with a weight-related comorbid condition. Those are international cut-offs, not adjusted for Asian bodies.

Our criteria are a BMI of 25 and above alongside a related health condition. If you are already taking a GLP-1 medication, that range may not apply to you.

They are different numbers answering different questions: the label licenses a product, our criteria decide who this service can start a conversation with. Meeting them is not the same as being suitable for treatment, which a doctor decides at the consultation. The three published Singapore BMI scales and how they relate are set out in am I eligible.

What the trials showed

SURMOUNT-1 enrolled 2,539 adults with obesity, or overweight with at least one weight-related complication, and without diabetes. Mean weight change at 72 weeks was −15.0% at 5 mg, −19.5% at 10 mg and −20.9% at 15 mg, against −3.1% with placebo. In the 15 mg group, 57% lost at least a fifth of their body weight (Jastreboff 2022).

Those are averages in a studied population, with lifestyle support in both arms. Individual results vary and are not guaranteed. How this compares with semaglutide is a question with one direct trial behind it, covered in semaglutide vs tirzepatide.

Why it is called a dual agonist

Because it acts at two receptors rather than one: GLP-1, like the rest of the class, and also GIP.

Both are gut hormones released when you eat, and both feed into the systems that govern appetite and blood sugar. Acting at both is the design difference between this molecule and semaglutide, and it is the likeliest explanation for the difference in the trials. The class mechanism is covered in how GLP-1 medications work.

Two things the Singapore label does not carry

No cardiovascular risk-reduction indication. Semaglutide 2.4 mg has one here; tirzepatide does not. That is a real difference between the two licences and it is not a comment on either medicine.

No sleep apnoea indication. This one matters because a headline exists. A separate United States application for tirzepatide had an efficacy supplement approved on 20 December 2024 (Drugs@FDA), and its United States prescribing information carries an indication to treat moderate to severe obstructive sleep apnoea in adults with obesity (DailyMed). That approval is American. It has no effect on what any doctor in Singapore may prescribe, and a Singapore reader acting on it is acting on a licence that does not exist here.

In the Singapore labels, sleep apnoea appears only as one of the comorbidities that can qualify an overweight person for weight management. What weight loss does and does not do for the condition itself is covered in sleep apnoea and body weight.

The number that is not on the label

A 2026 network meta-analysis pooled 262 trials and 99,791 participants across 19 drugs. Tirzepatide reduced fat mass the most, by 25.7% — and lean mass the most, by 8.3% (Nong 2026). Those are pooled trial averages, and individual results vary.

Both halves of that finding are the finding. More total loss is not automatically a better outcome if more of it is muscle, and it is not automatically a worse one either. It means the plan around the medicine — protein, resistance training, the rate of loss — matters more with the most effective agent, not less. We cover what the evidence shows about lean tissue in how much muscle you lose on GLP-1 medication.

Which medicine, if any, is appropriate for someone is a clinical decision made after an assessment. GLP-1 medicines may be dispensed here only against a valid prescription from a registered doctor (MOH 2024).

Common questions

Is the tirzepatide injection approved in Singapore for weight loss?

On its current registrations, yes. The KwikPen registrations from June 2025 and the vial registrations from October 2025 carry two headed indications in section 4.1 — type 2 diabetes mellitus, and weight management (NDF). The older 2023 injection registration carries type 2 diabetes only (NDF).

Why do some pages say it is diabetes-only in Singapore?

Because they are describing the 2023 registration, which is diabetes-only and is still on the register (NDF). Eighteen tirzepatide products are registered here in three generations, and they do not all carry the same indications. Any statement about what tirzepatide is licensed for in Singapore needs to say which registration it means.

It is approved for sleep apnoea. Does that apply here?

No. That approval belongs to a separate United States application, whose efficacy supplement was approved on 20 December 2024 (Drugs@FDA) and whose United States label carries the sleep apnoea indication (DailyMed). No GLP-1 medicine carries a sleep apnoea indication in Singapore. Sleep apnoea appears in the local weight-management indication only as a comorbidity that can qualify someone for treatment of their weight.

How much weight did people lose in the trials?

In SURMOUNT-1, mean weight change at 72 weeks was −15.0%, −19.5% and −20.9% at the 5 mg, 10 mg and 15 mg doses, against −3.1% with placebo, across 2,539 adults (Jastreboff 2022). Those are trial averages. Individual results vary and are not guaranteed.

Does the label's BMI of 27 mean GetLean's threshold is 27?

No. They are different numbers answering different questions. The registered label sets the floor for that product's weight-management indication. Our criteria are a BMI of 25 and above alongside a related health condition. If you are already taking a GLP-1 medication, that range may not apply to you. They decide who we can start a conversation with rather than who gets a prescription.